PitchBook clients can access the full report and its Excel data pack via the Research Center on the PitchBook Platform.
Pharma services sector sees momentum stall
Pharma services encompasses contract and outsourced services provided to the biopharmaceutical industry across the drug development and commercialization lifecycle. The sector emerged as a popular area of PE investment in 2022 and 2023, but its momentum has since stalled as the biopharma industry has undergone an extended funding drought and regulatory changes have delayed dealmaking.
Segments most exposed to weakening demand were hardest hit, with the outsourcing and clinical services segments seeing 26.9% and 39.7% YoY declines in transaction volume, respectively. Subsegments more insulated from funding and regulatory volatility fared comparatively better, with manufacturing and consumer health services seeing stronger relative deal counts.
Table of contents
| PE activity | 3 |
| Pharma services PE ecosystem market map | 10 |
| Pharma services PE investor map | 11 |
| 2025 timeline | 12 |
| Segment data | 13 |
| Outsourcing | 14 |
| Clinical services | 15 |
| Consulting services | 16 |
| Manufacturing & distribution | 17 |
PE transaction counts in pharma services fell significantly in 2025 as biotech funding (a leading indicator of pharma services demand) remained muted and regulatory changes created uncertainty throughout the year.